Trials / Recruiting
RecruitingNCT06828328
A Study of GC203 TIL in PDCA (RJ)
A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Pancreatic Ductal Adenocarcinoma
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Shanghai Juncell Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Conditions
- Pancreatic Cancer
- Pancratic Ductal Adenocarcinoma
- Treatment Side Effects
- Tumor Infiltrating Lymphocytes
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC203 TIL | the candidates will be assigned to GC203 TIL(gene-edited TIL) group |
Timeline
- Start date
- 2025-02-10
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
- First posted
- 2025-02-14
- Last updated
- 2025-12-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06828328. Inclusion in this directory is not an endorsement.